04/19/2023 1
“Litz” Blitz 2013Top Articles in Pediatric Hospital Medicine
A review of recent literature impacting the practice of pediatric medicine
Benjamin D. Bauer, MD, FAAP June 1st, 2013
Disclosure Statement
• Benjamin D. Bauer:–Has no relevant financial
relationships to disclose.–Has no conflicts of interest to
resolve.• This presentation will not involve
discussion of unapproved, off-label, or experimental interventions or medications.
04/19/2023 2
Strategy & Criteria for Article Selection:
• Reviewed literature from the past 18 months:– Pediatrics, Hospital Pediatrics, JAMApeds, JAMA,
NEJM<, Archives of Pediatrics & Adolescent Med, Journal of Pediatrics, Pediatric Infectious Disease, Journal of Hospital Medicine, Pediatric Emergence Care
• Selection based on general interest and potential to impact practice of pediatric hospital medicine
• General guidelines of the 3 R’s:– Recent, Relevant and Reputable.
04/19/2023 3
Strategy & Criteria for Article Selection:
• Final selection of articles, also considered ‘clinical grouping’ based on areas of interest to pediatric hospitalists
• Here are the clinical topics that will be covered in today’s talk:
1. Febrile Neonate / SBI
2. Fluid management
3. Failure to Thrive
4. Gastroesophageal Reflux
5. Hyperbilirubinemia
6. Bronchiolitis
7. Pneumonia04/19/2023 4
Disclaimer:
• Literature presented was chosen based general interest of the presenter
• No claim made regarding whether these are the most well-designed studies on a given topic
• The literature discussed should be critically and individually reviewed before change in practice is implemented
• Feel free to throw rotten fruit… but kindly wait until the end of the presentation
04/19/2023 5
The Febrile Infant
04/19/2023 6
04/19/2023 7
Background
• Serious Bacterial Infection (SBI) evaluation remains a challenge
• SBI Rates as high as 10-12% <3mo of age– UTI accounts for majority of SBI– Bacteremia and meningitis are less
common
• Risk stratification strategies have been developed; remain controversial
• Even those suggesting less invasive strategies push for LP prior to starting antibiotics
Background / Study Objective• Rochester Criteria for Febrile
Infants:– Infant appears well– Infant has been previously healthy– No evidence of skin, bone, joint or ear
infection – Labs: WBC 5K – 15K; Bands < 1,500;
< 10 WBCs in U/A; No pus in stool– When ALL criteria met; NPV for SBI is
98.9%
• Study Aim: Necessity of performing routine LP in well appearing 30-90 day old febrile infant with U/A suggestive of UTI
04/19/2023 8
Study Methods• Retrospective Study• Tertiary care children’s hospital ED; 200
pt/day• 4 year period; October 2001 – August
2005• Identified all febrile infants 30-90 days
of life:– underwent full sepsis work-up: LP for
culture, blood culture, urine culture and urinalysis.
• Exclusion Criteria: Premature (<35wk), chronic conditions, pre-culture antibiotics, or localizing infection on presentation
04/19/2023 9
Results:
04/19/2023 10
•Highlights:• 392 patients included • 61% male (241/392)• Mean age 56 days• Overall Rates of
Infection:• SBI: 60/392 (15.3%)• UTI: 52/392 (13.3%)• Sepsis: 13/392
(3.3%)• Meningitis: 4/392
(1%)• Only 1 patient with
both abnormal U/A and Meningitis
N = 39230-90 day febrile
infants full sepsis evaluation
Urine only46 patients
Urine & Blood5 patients
Urine, Blood & CSF
1 Patient
1 + Culture52 patients
2 + Cultures7 patients
3 + Cultures1 patient
Blood & Urine5 patients
Blood & CSF2 patients
Blood, Urine & CSF
1 patient
CSF only1 patients
CSF & Blood2 patients
CSF, Blood & Urine
1 patient
Blood only5 patients
CSF, Blood & Urine
1 patient
Results
• 1 patient with both abnormal U/A and meningitis
• 71 day old female:– Urinalysis: LE+, Nitrite+, 4WBCs/HPF– WBC: 2.9 x 109
– Cultures: E. coli (Blood, Urine and CSF)– Clinical: 38.5◦C, irritable, lethargic,
mottled
• NOT Low Risk by Rochester: Based on signs/sx would have undergone full sepsis work up
04/19/2023 11
Patients with meningitis
04/19/2023 12
Results
• Of the 388 infants without meningitis:– 56 (14%) had an abnormal U/A– 51 (13%) had a culture positive UTI
• Negative Predictive Value (NPV): – 98.2% NPV– 100% NPV, if Rochester ‘low risk’ criteria
are met
• Does not change the overall NPV of the Rochester criteria, but does potentially add to discussion regarding risk of meningitis
04/19/2023 13
Study Limitations
• May not generalize: Tertiary Care ED vs.. outpatient
• Small sample size: Decreases power to identify the potential case of meningitis in this population
• Retrospective design: Impossible to confirm that all “NON-low risk” infants actually underwent full septic work-up.
• Underestimates downstream impact: Does not acknowledge difficulty for those making decisions regarding management, if LP not done at antibiotic initiation.
04/19/2023 14
Clinical Bottom Line
• Study confirms findings of others:– Combined UTI and meningitis is
uncommon in infants <90 days of age ( 0% – 0.3%)
• Routine LPs may not be necessary in infants 30-90 days of life, if otherwise low-risk based on Rochester criteria
• If any uncertainty, or patient not well appearing then an LP MUST BE DONE prior to starting antibiotics
04/19/2023 15
In search of the 24 hour discharge…
04/19/2023 16
Background
• The management of the febrile infant is evolving
• Still common for infants with fever and no clear source to remain in hospital receiving empiric treatment for 48hrs while culture results mature
• Some institutions have used available evidence to push the LOS envelope for these patients…
04/19/2023 17
Evidence Based Care Process Model
04/19/2023 19
Study Objectives
• To determine if bacterial cultures in young infants would produce results in <36 hours
• With enough reliability to allow for discharge of otherwise healthy infants earlier than the standard 48 hour observation period
04/19/2023 20
Methods• Retrospective chart review• Oct 2007 – Feb 2011 (3 yrs 4 months)• All positive culture results (Blood, Urine,
CSF)• Drawn on infants 0 – 90 days of age
during the evaluation of SBI in ED or as inpatient
• Exclusion: Any indwelling lines, shunts, catheters; any cultures drawn while in ICU setting; significant underlying condition; repeat cultures taken from same patient during same stay
04/19/2023 21
Results• 283 patients with positive cultures• 2092 Blood cultures were drawn
– 38% (38/101) of blood cultures = true pathogens
– Mean time to detection (TTD) 13.3 hours (vs.. 25 hrs)
• 2283 Urine cultures were drawn– 58% (111/192) of urine cultures = true
pathogens– Mean TTD 21 hours (vs.. 26.7 hrs)
• 1159 CSF cultures were drawn– 50% (7/14) of CSF cultures = true pathogens– Mean TTD 28.9 hours (vs.. 57.7 hrs)
04/19/2023 22
Time To Detection of Bacterial Cultures
04/19/2023 23
Bottom Line
• This article adds to existing data about management of febrile neonate– Already excellent data to help with risk
stratification (Rochester criteria…)– Those infants admitted to the hospital
as ‘Low Risk’ have SBI rates in range of 1-3%
• In the appropriate clinical and social context – May consider discontinue antibiotics
therapy at 36 hours 04/19/2023 24
Fluids Management
04/19/2023 25
Background
• Hospital acquired hyponatremia is common
• Neurologic morbidity and death have been documented as a result of iatrogenic hyponatremia
• Has raised questions regarding 50yr standard of using Holliday-Segar recommendations for calculating parenteral maintenance fluids
• Growing evidence emerging that the use of isotonic fluids may decrease risk
04/19/2023 26
Study Objectives
• Fully blinded, randomized controlled trial
• Determine whether isotonic solution administered as maintenance IV fluids decrease the risk of hyponatremia when compared to hypotonic fluids
• Population: euvolemic pediatric patients in the acute post-operative period, with non-emergent reasons for surgery; requiring MIVF for 48hrs
04/19/2023 27
Study Methods• IRB approved, Blinded, RCT• Tertiary care children’s hospital, Canada• Randomly assigned to receive base
parenteral maintenance solution (PMS) of either 0.45% saline (hypotonic) or 0.9% saline (isotonic)– Dextrose (D5) present in both– Potassium added according treating MD
request
• 6mo – 16yrs; euvolemic; within 6hrs of non-emergent surgery; likely to need MIVF >24hrs04/19/2023 28
Study methods / Outcome measures
• Plasma sodium, Urine sodium/potassium and ADH measured every 12 hours
• Intervention was started immediately post-op and continued for maximum of 48hrs
• Primary Outcome: Hyponatremia; ≤ 134mmol/L
• Secondary Outcomes: Severe hyponatremia (≤ 129mmol/L), hypernatremia (≥ 146mmol/L), plasma ADH levels, adverse events, and patients who changed fluids during study (reason)
04/19/2023 29
Results • 3/2008 – 12/2009• 728 patients screened• 427 eligible• 258 were enrolled• 128 randomized to
isotonic fluid• 130 randomized to
hypotonic fluid• 4 patents from each
group withdrew during study
• 32 patients lacked data
04/19/2023 30
18 lackeddata
14 lacked data
04/19/2023 31
• Baseline characteristics
between groups is similar
• 77 of 258 (29.8%) admitted
to ICU postoperatively
• No differences in baseline
sodium or fluid intake
• Only 16 (6%) had pre-op
sodium levels ordered
• Median time to starting fluid
intervention was 22minutes post operatively (6hrs max)
• Most common surgery: Orthopedic, General, Urologic
Results: Primary Outcome
• Primary Outcomes: Risk of hyponatremia was higher in the hypotonic fluid group:
04/19/2023 32
Results: Secondary Outcomes
• Plasma ADH levels on POD#1 elevated in both groups, but no difference (P= .208)
• Subgroup analysis showed PICU patients at NO higher risk after adjusting for fluid type (P= .105)
• 15 pts changed to open-label isotonic fluids– 12 (9.2%) vs.. 3 (2.3%); P = .036 (Hypotonic) (Isotonic)
• with ‘Hyponatremia’ most common cited reason– 1 (0.8%) vs.. 7(5.4%); P = .033 (Hypotonic) (Isotonic)
04/19/2023 33
Study Limitations
• Well-designed, blinded, randomized trial• May Not Generalize: Did not include
patients requiring emergency surgeries; did not include non-surgical patients
• Baseline Comparison Data: Most patients in study did not have ‘baseline’ lab values prior to enrollment
• Missing Data: Not all patients included in study had all planned samples drawn.
04/19/2023 34
Clinical Bottom Line• Risk of hyponatremia is significantly
higher in post-op patients receiving hypotonic fluids
• Relative risk reduction of 44% with isotonic fluid
• NNT to prevent 1 case of hyponatremia = 6
• Isotonic fluid use does not appear to increase adverse events or lead to hypernatremia
• Current standard of post-operative fluid management should be re-evaluated… – Isotonic fluid may be safer!
04/19/2023 35
Failure to Thrive
Background
• Failure to Thrive (FTT) is common– As many as 10% of general pediatric patients
• Outpatient management of failure to thrive “is fraught with difficulties because trying to organize a cohesive approach… is logistically challenging.”
• Often assumed that admission may be the more efficient approach, with goal of coordinating multiple resources needed to diagnose and treat
• FTT: Up to 5% of all admissions for children less than 2 years of age
Background
• Heavy resource utilization for these patients:– Labs, imaging, speech, nutrition, social
work, and subspecialist consultation
• Limited access to many of these resources during the weekend; even at large tertiary referral centers
• Is the weekend the best time to admit these patients to the hospital?
Study Objectives
• To evaluate whether weekend admission of Failure to Thrive:1. Affects the length of stay (LOS)2. Affects the overall cost of the
admission
04/19/2023 39
Methods
• PHIS database– Administrative data from 43 free-
standing children’s hospitals
• Inclusion Criteria:– 2003-2011 (9 years of data)– All Children <2 years with primary admit
diagnosis of Failure to Thrive
• Data: Demographics, LOS, day of admit, diagnoses, procedures, tests, charges/costs
Results
• 23,332 patients met inclusion criteria• Median age: 7.5 months
– 43.8 % (10,222) less than 6 months of age
• Weekend admissions STAYED LONGER– LOS increased by 1.93 days (IRR: 1.20
[95% CI 1.18-1.22]
• Weekend admissions COST MORE– Mean cost increase of $2785 per
admission
04/19/2023 41
FTT on Weekends: Cost More, Stay Longer
Results
Limitations:
• PHIS database limitations• Used surrogate data to make
assumptions about how ‘sick’ patients were
• Institutional bias in financial reporting is possible
04/19/2023 44
Author Bottom Line
•Acknowledging that some of the weekend admissions had medical issues requiring immediate inpatient attention…•If HALF of the weekend admissions over the study period were simply converted to Monday admissions:
– total savings in health care dollars would be in excess of $500,000 per year– or > $3.5 Million over the study period
Gastroesophageal Reflux
04/19/2023 46
Background
• Diagnosis and management of GERD remains challenging for families and pediatricians
• From 1999 to 2004, 7-fold increase in use of prescription medication in infants with GERD
• Growing evidence that acid reducing medications are NO BETTER than placebo in treating symptoms of GERD
• Growing concern regarding safety of these agents in both adults and children
04/19/2023 47
Mechanism for increased infection Risk?
• Gastric Acid is a known non-selective barrier to infection
• Most pathogens will not survive at pH < 4 (normal gastric acidity)
• Suppression of acid production may allow bacterial colonization and overgrowth (including pathogenic organisms)
• PPIs & H2 Blockers may also directly inhibit leukocyte activity; thereby blunt immune response
04/19/2023 48
Objectives & Methods• Review of literature• Evaluate potential serious adverse
effects associated with acid-suppressing medications in the pediatric population
• PubMed Search: English Language, 0-18 yrs
• Limited to original placebo controlled studies OR studies with comparison to non-acid suppression which specifically evaluated adverse events as part of study04/19/2023 49
Results
• 14 studies met inclusion criteria• 6 NICU studies• 5 PICU studies• 3 Non-Critical Care Population Studies• Both H2 Blockers and PPIs represented• Associate adverse events primarily
‘infectious’ in nature
04/19/2023 50
14 Studies Reviewed
04/19/2023 51
NICU Population• Necrotizing Enterocolitis (NEC): 2 Studies
1. Retrospective Case-Control Study of H2-blockers:• 787 infants with NEC• Use of H2-Blocker increased risk of
NEC– OR: 1.71 [95% CI: 1.34-2.19], P<.001
2. Prospective Multicenter Observation, ranitidine• 274 infants; 91 got ranitidine, 183 did not• Increased risk of infection; Sepsis
and pneumonia– OR 5.5 [95% CI: 2.9-10.4], P<.001
• Increased risk of NEC– OR 6.6 [95% CI: 1.7-25], P=.003
04/19/2023 52
NICU Population
• Infection Risk: 4 Additional Studies1. H2 Blockers & Blood Infections:
• Prospective Study: 376 infants, 42 bacteremia
• H2 Blocker increased risk: OR 2.9; P=.0082. Nosocomial Bacterial Infections:
• Prospective Study: 1504 infants, 127 infections
• H2 Blockers incr. risk: OR 7.3 [95% CI 3.9-13.6]
3. Late Onset Sepsis:• Retrospective review: 569 infants; 74
sepsis• Sepsis pts more likely to have received
ranitidine– OR 6.99 [95% CI: 3.78-12.94], P<.0001
04/19/2023 53
PICU Population• 4 Studies: Ventilator-Associated
Pneumonia (VAP) and Acid Suppressor medication
• 2 Studies found association:– Prospective Study: 595 ventilated
patients• 34 VAP episodes; univariate analysis
showed association with H2 blockers• 47% of VAP patients had received H2
blockers vs. 24% of Non-VAP patients; P=.006
– Prospective Study: 40 patients; 8/40 with VAP• 63% of VAP patients had received H2
blockers vs. 22% of Non-VAP patients; P=.025
04/19/2023 54
Non-Critical Care Population• PNEUMONIA: 2 Studies
1. Canani et al: Prospective multicenter cohort • 4 - 36 mo of age; GERD diagnoses by pH
monitor & esophageal biopsy• H2-Blocker or PPI for 2 month course• 11% of 91 developed pneumonia vs. 2%
of healthy controls (P<.05)2. Orenstein et al: Randomized controlled
trial • Lansoprazole vs. placebo for GERD in
infants• Serious Adverse event in 12% of 81
infants in PPI vs. 2% of 81 patients in placebo; PNA most common
04/19/2023 55
Non-Critical Care Population• Gastrointestinal Infections: 2 Studies
1. Canani et al: Prospective multicenter cohort • 4 - 36 mo of age; GERD diagnoses by pH
monitor & esophageal biopsy• 91 patients; H2-Blocker or PPI for 2 month
course• 47% those patient developed acute
gastroenteritis vs. 20% of healthy controls – OR: 3.58 [95% CI 1.87-6.85] P=.001
2. Turco et al: Retrospective study: PPI and C.Diff• Higher rates of C.diff associated disease
(CDAD)– OR: 4.52 [95% CI: 1.4-14.4)
04/19/2023 56
What’s in a Name?
04/19/2023 57
Bottom Line: First, Do No Harm
• With the Exception of endoscopically confirmed erosive esophagitis, Acid blocking medications have NOT been shown to be of benefit in young infants with GERD symptoms
• Conservative therapies, while more difficult and time consuming do have some evidence behind them (decreased volumes, thickening feeds)
• CHOOSING WISELY: “Don’t treat GER in infants routinely with acid suppression therapy.”04/19/2023 58
Hyperbilirubinemia
04/19/2023 59
Background
• Jaundice in newborns is incredibly common
• Indirect bilirubin is a neurotoxin that can cause both acute and irreversible injury to the brain
• Phototherapy is the cornerstone of effective treatment of hyperbilirubinemia in newborns; safe & effective
• Evidence based guidelines published by the AAP in 2004 and updated in 2011 Technical report
04/19/2023 60
Background: Efficacy of Phototherapy• Efficacy of Phototherapy in reducing Total
Serum Bilirubin (TsB) levels depends on 4 factors:– Wavelength of light emitted from source (nm)– Intensity of light (Spectral Irradiance -
µw/cm²/nm)– Surface area exposed to light– Duration of exposure to light
• AAP has defined ‘Optimal Phototherapy’ as:– Visible Blue light (460-490nm), – Delivered at ≥ 30 µw/cm²/nm (Intensive
Phototherapy)– To the largest possible body surface area
04/19/2023 61
Background: Dose-Response Curve
• Established dose-response data allowed AAP to set 30 µw/cm²/nm as definition of “intensive phototherapy”
• Previous Studies suggest “Saturation Point” above which additional intensity provides no further benefit in terms of rate of TsB drop
• Old data based on equipment with ‘Minimum distances to baby’ based on concern for thermal injury
04/19/2023 62
Objectives
• To use newer LED technology to investigate Dose-Response curve for hyperbilirubinemia
• To see if increasing intensity (spectral irradiance) of phototherapy is associated with increase rate of drop of TsB in patient
• To see if increasing intensity (spectral irradiance) of phototherapy is associated with a ‘saturation point’
04/19/2023 63
Methods
• Prospective, randomized treatment trial• NICU in Denmark; July 2009 –
December 2010• Inclusion Criteria: Healthy Neonates,
>33wks , uncomplicated hyperbilirubinemia, open bassinet.
• Exclusion Criteria: Known hemolytic disease, patients requiring exchange transfusion, patients with Total Bili rise > 0.5mg/dl/hr, <24hrs of age at time of initiation of photothx
04/19/2023 64
Methods• Equipment Used:
– NATUS, neoBLUE LED bank system– ‘High’ setting only
• Randomized to 1 of 4 phototherapy regimens:– Based on distance to mattress in 3.5”
increments: 8”, 11.5”, 15”, 18.5”– Avg to baby: 5”, 8.5” , 1 2”, 15.5”
• Babies received continuous phototherapy x 24h
• Diapers & goggles only, out to feed 30m Q 3h
04/19/2023 65
Results: 151 infants
04/19/2023 66
Bottom Line
• As intensity of light increases, the rate of TsB-drop increases.
• While not specifically studied in this article, it is reasonable to assume that, if TsBili decreases faster, LOS will decrease.
• With NEOblue LED unit a distance of 5” produces spectral irradiance of up to 55 µw/cm²/nm– Which should drop TsB by 50% in 24hrs
04/19/2023 67
Bronchiolitis• What fun thing should we try this year?• How can we tell which kids are going to
crump?– Could this help us plan for shorter stays
and earlier discharges?
• Hospitalist “Hands Across America”– Can we impact change? Yes we can!– And no body does it better
04/19/2023 68
Suctioning & LOS in Bronchiolitis:
Background
• The mainstay of bronchiolitis therapy is supportive
• Suctioning management and its efficacy is largely unstudied
• Nasal suction provides a temporary relief of symptoms
• Pharmacologic treatment of nasal obstruction has not been shown to have significant impact on outcomes*
Objectives
• To determine if repeated nasopharyngeal suctioning (“deep suction”) produces worse outcomes (“is harmful”) when compared to noninvasive suctioning
• To determine if frequent suctioning improves clinical outcomes
Methods
• Retrospective cohort study:– Cincinnati Children’s (CCHMC) & Satellite Facility– 2 - 12 month-old infants hospitalized with
bronchiolitis; January 2010 – April 2011– Exclusion: < 2mo old; ICU admit; tracheostomy
• Charts reviewed for:– Suction Device type – Time lapses in suctioning (>4hrs)
• Primary Outcome Measure: Length of Stay (LOS)
Results: 740 infants in Device Type cohort
• Multivariable analysis:
LOS = 0.6 days longer in >60% group vs.. None group
P = <.001
Results: 695 in Suctioning Frequency cohort
• Multivariable analysis:
LOS = 1.02 days longer in > 3 lapses group vs.. 0 lapses group
P = <.001
Limitations
• Device Type Cohort: ‘Confounding by Indication’– Nurses and RTs may have chosen deep
suctioning for patients who were ‘sicker’– “Confounding by indication for deep
suctioning may be a source of systematic error… results should be interpreted with caution in this context.”
– A prospective study that randomizes suction device type is needed
04/19/2023 75
Bottom line
• Nasopharyngeal suctioning may have negative impact on outcomes & may prolong LOS
• Scheduled, non-invasive nasal suctioning may have a positive impact on length of stay
• Idea for your next study!
Trying to predict who is going to crump?
May be the only study that matters…
• It’s not for lack of trying… but so far, we all know the truth: Nothing that we do clinically seems to change outcomes or LOS
• As we look for ways to safely impact LOS and outcomes in bronchiolitis, One question does become very important…
Which of these little boogers is going to crump and need to go to the ICU?
Objective & Methods• To identify risk factors associated with
progression to need for CPAP and/or intubation for children with bronchiolitis
• Prospective, multicenter cohort study– 16 centers: Multicenter Airway Research
Collaboration (MARC)
• 2007-2010: 3 consecutive winter seasons• Inclusion: <2 yrs admitted with
bronchiolitis
04/19/2023 79
Results
• 2207 children enrolled in study– 379/2207 (17%) enrolled in the ICU
• Of 379 ICU patients, 161 (42%) required CPAP and/or intubation
• RSV A/B accounted for 73% of detected pathogens – Viral etiology was not an overall
predictor of progression to intubation*
04/19/2023 80
Independent Predictors of CPAP/ETT• 4 History Predictors:
– Age: < 6mos at presentation– Birth weight: < 7 lbs (3.18kg)– Maternal smoking during pregnancy– Breathing difficulties < 1 day prior to ED
visit
• 4 Clinical Predictors:– Apnea– Severe retractions– Oxygen saturation < 85%– Inadequate oral intake
Independent Risk Factors: By the NumbersCharacteristic Detail Odds Ratio 95% CI
Age (months) < 2 4.29 1.66 – 11.53
2 – 5.9 2.61 1.16 – 6.10
Birth Wt (pounds) < 5 1.70 1.01 – 2.52
≥ 5 - < 7 1.68 1.03 – 2.68
Smoked in Pregnancy
YES 1.38 1.05 – 1.91
Onset Breathing Difficulty
< 1 day 1.58 1.15 – 2.09
Apnea YES 4.78 2.57 -8.50
Retractions Severe 11.14 2.40 – 33.19
Oxygen Saturation, RA
<85% 3.28 2.02 – 4.82
Oral Intake Inadequate 2.51 1.34 – 4.26
04/19/2023 82
Bottom Line
• Smoking is bad!• There are historical and clinical risk
factors that can be used to predict possible progression of disease and need for ICU
• How can these be used?– As teaching tools for clinicians– As components of evidence-based care
process models used to shorten LOS and decrease hospital admissions…
04/19/2023 83
Knowing the risk data CAN impact care
04/19/2023 84
Yes We Can!
04/19/2023 85
A glimmer of hope…
Percentage Change in Resource Utilization by Year
2007 2008 2009 20100
10
20
30
40
50
60
70
80
Bronchodilators (p<0.01)
Chest Radiography (p=NS)
RSV Testing (p=NS)
Steroids (p=NS)
Chest Physiotherapy (p<0.01)
04/19/2023 87
And if anybody can do it…
Pneumonia
Objectives & Methods• Describe variability in resource utilization for
children hospitalized with Community-Acquired Pneumonia (CAP)
• Retrospective Cohort study using PHIS database• July 2005 – June 2010 (5 years of study data)• Children 1 – 18 years of age, with “non-severe
CAP”– ( ± effusion or empyema )
• Primary Exposure of Interest: Hospital-Level initial resource utilization on DAY 1
• Measured Outcomes: LOS, Readmission Rates
Results
• 43,819 Children Hospitalized with CAP• After exclusion criteria applied: 21,213
patients• Median Age: 3yrs – 72% were between 1-5
yrs– 22% were 6-12 yrs– 5% were 13-18 yrs
• LOS: 2 days (IQR: 1-3 days)– 25% of <12 yr olds hospitalized > 3 days– 25% of 13-18 yr olds hospitalized > 4 days
• Readmission Rate: Overall 2.3% (higher in 13-18yr)
04/19/2023 91
Results: Substantial Variation in Resource Utilization seen at the Hospital Level
Results: Variation in antibiotic use
Hospital - level variation in empiric antibiotic therapy among children with CAP. Each column on the x-axis represents data from one hospital.
Institutions that performed more diagnostic testing had longer LOS
Bottom Line
• The more you do… The longer they stay
• Earlier discharge DID NOT correlate with increased 14 day readmission
04/19/2023 95
Macrolide combination therapy in CAP
04/19/2023 96
Objective & Methods
• Determine the effectiveness of β-lactam monotherapy when compared with β-lactam PLUS macrolide in pts hospitalized with CAP
• Retrospective Cohort Study Using PHIS• January 2006 – December 2008 (3
years)• Children 1 – 18 yrs; with non-severe
CAP• Primary Exposure of Interest: Empiric
antibiotic• Outcome Measures: LOS, 14-day
Readmissions
04/19/2023 97
Results
• 37,461 patients eligible based on ICD-9 coding
• After Exclusion Criteria applied: – 20,743 patients included– 76% received β-lactam monotherapy– 24% received β-lactam PLUS macrolide
• Variability across sites:– Combination tx ranged from 17% - 48%
• LOS: Median length of stay for cohort: 2 days
04/19/2023 98
Results
• In the adjusted analysis:– Average LOS for patients receiving
combination therapy was 20% less than monotherapy
– When age was factored in older children saw largest drop in LOS• 6-11 yr old saw 25% reduction in LOS• 12-18yr old saw 31% reduction in LOS
– 1-5 year olds saw no benefit in LOS reduction
• No significant decrease in readmissions seen04/19/2023 99
Bottom Line
• 5-18 yo CAP inpatients may benefit from addition of macrolide therapy to standard empiric β-lactam therapy (AMPICILLIN!)
• Findings of are in concordance with 2011 IDSA guidelines, which make macrolide a ‘combination option’ for patients in whom atypical organisms “are a significant consideration”– Namely, school age children and
adolescents
• Randomized clinical trials are needed.04/19/2023 100
Thank You!
04/19/2023 101
Top Related